A fundamentally different approach to treating autoimmune conditions may emerge from targeting B-cells without destroying them entirely. This paradigm shift could preserve immune function while controlling harmful autoimmune responses that characterize complex inflammatory diseases. Obexelimab represents a novel therapeutic strategy that modulates B-cell activity rather than eliminating these crucial immune cells. Unlike conventional B-cell depleting therapies such as rituximab, this antibody-based treatment selectively inhibits B-cell function while maintaining the cellular population intact. In IgG4-related disease, a rare but serious autoimmune condition affecting multiple organs, obexelimab demonstrated the ability to control inflammatory responses without the profound immunosuppression associated with cell-depleting approaches. The mechanism involves targeting specific B-cell surface receptors that regulate activation and antibody production. This selective modulation allows the immune system to retain its protective capabilities while reducing the production of pathogenic antibodies that drive tissue damage in autoimmune diseases. The implications extend beyond IgG4-related disease to potentially reshape treatment approaches across the autoimmune spectrum. Traditional B-cell depletion carries significant infection risks and requires months for immune reconstitution. Nondepleting therapies could offer comparable efficacy with improved safety profiles, particularly valuable for older adults or those with compromised immune systems. However, this represents early-stage clinical development, and long-term safety data remains limited. The approach requires validation across diverse autoimmune conditions and patient populations. Success could establish a new therapeutic class that balances immune modulation with preservation of protective immunity, addressing a critical limitation of current autoimmune treatments.